Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma.

Trial Profile

Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Plerixafor (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Dana-Farber Cancer Institute
  • Most Recent Events

    • 31 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 31 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
    • 18 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top